Fresh from a CAN$32.3m ($25.9m) public offering in July, Cybin Inc. is focused on getting its lead candidate, CYB003, into the clinic for major depressive disorder (MDD) next year. However, the firm had quite a journey in its development of psilocybin drugs, a hotly anticipated class that has piqued investor interest.
Headquartered in Toronto, Canada, Cybin kicked off with a CAN$3.5m seed funding round. It was founded in 2019 by three people who shared personal experiences with friends and family suffering mental health disorders, CEO Doug Drysdale told Scrip
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?